NCT02023541终止1 期
A Phase I Study of Proton Beam Therapy in the Treatment of Esophageal Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- Progression-free survival
研究概览
简要总结
Assess progression-free survival and overall survival of proton beam therapy (PBT) for patients with resectable vs. unresectable esophageal cancer, and to assess patient-reported outcomes of PBT for esophageal cancer at 6 months following chemoradiation and physician-reported toxicity of PBT for esophageal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically documented adenocarcinoma or squamous cell carcinoma of the cervical or thoracic esophagus or gastroesophageal junction or cardia of stomach.
- •Staged by PET/CT and esophagogastroduodenoscopy (EGD) OR CT w/contrast and EGD to have stage II or III disease. Endoscopic ultrasound (EUS) is encouraged but not required.
- •Prior endoscopic mucosal resection (EMR) with a diagnosis of stage II or III esophageal cancer is eligible, irrespective of margin status.
- •Induction chemotherapy prior to concurrent chemoradiation is allowed.
- •Prior thoracic radiation is allowable if degree of overlap with the esophageal radiotherapy treatment is deemed to be safe by the treating radiation oncologist.
- •At least 18 years of age.
- •ECOG performance status ≤ 2 (Karnofsky > 60%)
- •Normal bone marrow and organ function as defined below:
- •WBC > 2,500/mcL
- •Platelets ≥ 75,000/mcl
- •Total bilirubin ≤ 1.5 x IULN
- •AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- •Creatinine ≤1.5 x IULN OR creatinine clearance ≥ 50 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
- •Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- •Ability to understand and willingness to sign an IRB approved written informed consent document.
- •English speaker.
- •Financial coverage for proton therapy.
排除标准
- •Planned treatment with radiation therapy alone without concurrent chemotherapy or chemotherapy alone.
- •Previous or concomitant cancers within the past 3 years other than curatively treated carcinoma in situ of the cervix, basal cell carcinoma of the skin, curative treatment for transitional cell carcinoma of the bladder, and low risk prostate cancer. Except for prostate cancer (which can be observed if low risk), other cancers listed must have been treated in the past 3 years without evidence of recurrence at the time of registration.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia not controlled by pacer device, myocardial infarction within 3 months of registration, or psychiatric illness/social situations that would limit compliance with study requirements
- •Pregnant and/or breastfeeding. Patient must have a negative pregnancy test within 7 days of study entry.
结局指标
主要结局
Progression-free survival
时间窗: 2 years
Assess progression-free survival (PFS) of PBT for patients with resectable vs. unresectable esophageal cancer. PFS will be assessed using the Kaplan-Meier estimate.
Overall survival
时间窗: 2 years
Assess overall survival (OS) of PBT for patients with resectable vs. unresectable esophageal cancer. OS will be assessed using the Kaplan-Meier estimate.
次要结局
- Patient-reported outcomes of PBT for esophageal cancer at 12 months following chemoradiation.(1 year)
- Quality of life(6 months)
- Toxicity(1 year)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
Phase II Study of Proton Radiation Therapy for NeuroblastomaGanglioneuroblastomaNeuroblastomaNCT02112617Massachusetts General Hospital30
招募中
1 期
A phase I/II study of proton beam therapy for early breast cancer evaluating safety and effectivenessBreast cancerJPRN-UMIN000017579Medipolis Proton Therapy and Research Center24
进行中（未招募）
2 期
Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) TrialEsophageal CancerNCT01512589M.D. Anderson Cancer Center147
招募中
不适用
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation TherapyPediatric Patients Treated With Radiation TherapyNCT01696721Massachusetts General Hospital5,000
尚未招募
2 期
Phase 2 trial of Proton Beam Therapy for malignancy pediatric tumor.Malignant pediatric tumor below the age of 20.JPRN-UMIN000026419niversity of Tsukuba2,000